BLA 761032 · Valeant Luxembourg
Siliq
Brodalumab · Injection · Interleukin-17 Receptor A Antagonist
NovelLast checked: Nov 20, 2026Latest source record: May 7, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Feb 15, 2017
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
46
14 Phase 3, 3 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Therapeutic areas: Immunology and inflammation
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Brodalumab" as an intervention, any sponsor and status, largest first.
- Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis SubjectsPivotal-lookingTerminated
Bausch Health Americas, Inc.Industry
NCT01708629 · 1,881 participants · Start Sep 2012 · Primary completion Aug 2014
Drug: 210 mg brodalumab; 140 mg brodalumab and 2 more · For: Plaque Psoriasis
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 157 sites in all
- P3 Study Brodalumab in Treatment of Moderate to Severe Plaque PsoriasisPivotal-lookingTerminated
Bausch Health Americas, Inc.Industry
NCT01708603 · 1,831 participants · Start Aug 2012 · Primary completion Sep 2014
Drug: 210 mg brodalumab; 140 mg brodalumab and 2 more · For: Moderate to Severe Plaque Psoriasis
Sites: Birmingham, Alabama; Tucson, Arizona; Hot Springs, Arkansas · 153 sites in all
- Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis SubjectsPivotal-lookingTerminated
Bausch Health Americas, Inc.Industry
NCT01708590 · 661 participants · Start Aug 2012 · Primary completion May 2014
Drug: 210 mg brodalumab; 140 mg brodalumab and 1 more · For: Psoriasis
Sites: Phoenix, Arizona; Bakersfield, California; Encino, California · 78 sites in all
- Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic ArthritisPivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT02024646 · 484 participants · Start Mar 2014 · Primary completion Oct 2015
Drug: 210 mg brodalumab; 140 mg brodalumab and 1 more · For: Psoriatic Arthritis
Sites: Peoria, Arizona; Little Rock, Arkansas; Cypress, California · 103 sites in all
- Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic ArthritisPivotal-lookingTerminated
Bausch Health Americas, Inc.Industry
NCT02029495 · 478 participants · Start Mar 2014 · Primary completion Oct 2015
Drug: 210 mg brodalumab; 140 mg brodalumab and 1 more · For: Psoriatic Arthritis
Sites: Huntsville, Alabama; Tuscaloosa, Alabama; Peoria, Arizona · 152 sites in all
- Study of Efficacy and Safety of Brodalumab Compared With Placebo in Adults With Inadequately Controlled Asthma With High Bronchodilator ReversibilityPivotal-lookingTerminated
AmgenAmgen (AMGN)
NCT01902290 · 421 participants · Start May 22, 2013 · Primary completion May 15, 2015
Drug: Placebo; Brodalumab · For: Asthma
Sites: Birmingham, Alabama; Glendale, Arizona; Phoenix, Arizona · 161 sites in all
- Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body WeightPivotal-lookingCompleted
LEO PharmaIndustry
NCT04306315 · 385 participants · Start Jul 21, 2022 · Primary completion Aug 25, 2025
Drug: Brodalumab · For: Psoriasis Vulgaris
Sites: Brussels, Belgium; Ham-sur-Heure-Nalinnes, Belgium; Leuven, Belgium · 81 sites in all
- A Study to Evaluate the Dosing of AMG 827 for Subjects With Inadequately Controlled AsthmaPivotal-lookingCompleted
AmgenAmgen (AMGN)
NCT01199289 · 315 participants · Start Oct 4, 2010 · Primary completion Dec 21, 2011
Drug: AMG 827; Placebo · For: Asthma
Sites: Encinitas, California; Huntington Beach, California; Los Angeles, California · 49 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Siliq (Brodalumab)
2024 spending
$8.5M
Beneficiaries
191
1,531 claims
Per beneficiary
$44,561
$1,694.79 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $9,379,407 |
| 2021 | $8,588,270 |
| 2022 | $9,014,594 |
| 2023 | $10,003,559 |
| 2024 | $8,511,214 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis.
Kerschbaumer A, Smolen JS, Ferreira RJO, et al. · Ann Rheum Dis 2024 · Systematic Review
- Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E, Chaimani A, Garcia-Doval I, et al. · Cochrane Database Syst Rev 2022 · Network Meta-Analysis, Research Support, Non-U.S. Gov't
- Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis.
Armstrong AW, Puig L, Joshi A, et al. · JAMA Dermatol 2020 · Comparative Study, Research Support, Non-U.S. Gov't
- Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E, Chaimani A, Guelimi R, et al. · Cochrane Database Syst Rev 2025 · Comparative Study, Network Meta-Analysis
- Biologics switch in psoriasis.
Wang TS, Tsai TF · Immunotherapy 2019 · Systematic Review
- Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E, Chaimani A, Guelimi R, et al. · Cochrane Database Syst Rev 2023 · Review, Research Support, Non-U.S. Gov't
Sponsor: Valeant Luxembourg
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.